Sector Expert: Robert Erwin
Robert L. Erwin is president of iBio Inc. He previously led Large Scale Biology Corp. from its founding in 1988 through 2003, including a successful initial public offering in 2000, and continued as non-executive chairman until 2006. Mr. Erwin served as chairman of Icon Genetics AG from 1999 until its acquisition by a subsidiary of Bayer AG in 2006. He is currently chairman of Novici Biotech, a private biotechnology company, and a director of Oryn Therapeutics LLC. Mr. Erwin's nonprofit work focuses on applying scientific advances to clinical medicine, especially in the field of oncology. He is cofounder and president of the Marti Nelson Cancer Foundation and a former member of the Cancer Policy Forum of the Institute of Medicine. Mr. Erwin received his bachelor's degree with honors in zoology, and a master's degree in genetics, from Louisiana State University.
The growing need for recombinant proteins for vaccines and therapeutics is causing the biotech industry to look beyond vat fermentation and cell cultures for protein expression systems that, like iBio Inc.'s iBioLaunch technology, can increase yields quickly, safely and inexpensively. In this interview with The Life Sciences Report, iBio's President Robert L. (Bob) Erwin describes the iBioLaunch technology and what it offers to drug developers and investors.